Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Blood clotting disorders" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Factor II, V, VII, X, or XII deficiencies are bleeding disorders related to blood clotting problems or abnormal bleeding problems. von Willebrand's disease is the most common inherited bleeding disorder. It develops when the blood lacks von Willebrand factor, which helps the blood to clot.
Nicotinamide riboside and analogues thereof
InactiveUS20060229265A1BiocideSaccharide with heterocyclic radicalsNicotinamide ribosideCompound (substance)
Provided herein are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Owner:GLAXO SMITHKLINE LLC
N-Phenyl Benzamide Derivatives as Sirtuin Modulators
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Owner:SIRTRIS PHARMA INC
Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
InactiveUS20120135091A1Extend your lifeImprove survivabilityBiocideOrganic chemistrySurvivabilityBiological materials
The present invention concerns the use of active compounds, including chalcogenides and sirtuin-modulating compounds, either alone or in combination for increasing or enhancing survivability and / or longevity in biological matter. In general aspects, the chalcogenides and other active compounds may modulate one or more sirtuin proteins. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability in any of these biological materials, so as to preserve and / or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
Owner:FRED HUTCHINSON CANCER RES CENT
Stimulus responsive nanocomplexes and methods of use thereof
InactiveUS20140364368A1Inhibit biological activityOrganic active ingredientsPeptide/protein ingredientsHypercoagulable statesMedicine
The present invention provides stimulus responsive nanocomplexes comprising a masking moiety, e.g., a peptide, and a therapeutic moiety, e.g., an anti-coagulant. The invention also provides methods for treating or preventing a condition, such as a hypercoagulable state, e.g., blood clotting disorders or a cardiovascular disease, in a subject.
Owner:MASSACHUSETTS INST OF TECH
Benzimidazole derivatives as SIRTUIN modulators
Owner:SIRTRIS PHARMA INC
Oxazolopyridine derivatives as SIRTUIN modulators
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treatin and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Owner:SIRTRIS PHARMA INC
Benzimidazole derivatives as SIRTUIN modulators
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treatin and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Owner:SIRTRIS PHARMA INC
Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
InactiveCN102317284AOrganic active ingredientsSenses disorderDiabetes mellitusPhosphodiesterase inhibitor
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.
Owner:SIRTRIS PHARMA INC
Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.
Owner:SIRTRIS PHARMA INC
Substituted bridged urea analogs as sirtuin modulators
Owner:GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD
Isoindolinone and related analogs as sirtuin modulators
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.
Owner:SIRTRIS PHARMA INC
Benzimidazole derivatives as SIRTUIN modulators
InactiveCN101282974AOrganic active ingredientsSenses disorderBenzimidazole derivativeImidazopyridine
Owner:SIRTRIS PHARMA INC
Substituted bridged urea analogs as sirtuin modulators
Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Owner:GLAXO SMITHKLINE LLC
Methods and compositions for improving pial collateral circulation and treating blood clotting disorders
InactiveCN104507468AImprove scoreEasy to primeOrganic active ingredientsFood ingredient functionsTissue inhibitor of metalloproteinasePharmacology
Owner:THE OHIO STATES UNIV
Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Owner:GLAXO SMITHKLINE LLC
Fibrils
InactiveUS20060128606A1Process can be speededProcessing speedNervous disorderHydrolasesMedicineHeart disease
An amyloid fibril substantially free of other protein is disclosed. Also disclosed are processes for preparing the fibril, and methods and uses of the fibril particularly in connection with treating diabetes, blood clotting disorders, cancer and / or heart disease.
Owner:DOBSON CHRISTOPHER M
In vivo gene therapy using delivery of a lentiviral gene construct
PendingCN112272565AOrganic active ingredientsPeptide/protein ingredientsAntiendomysial antibodiesCD8
Owner:SEATTLE CHILDRENS HOSPITAL (DBA SEATTLE CHILDRENS RES INST)
Pharmaceutical composition for treatment of blood clotting disorder
InactiveUS8217014B2Reduce the burden onReduce riskBiocidePeptide/protein ingredientsBlood clotting disordersRibavirin
Owner:NAGOYA UNIVERSITY
Pyridines, bicyclopyridines, and related analogs as sirtuin modulators
The present invention provides novel sirtuin-modulating compounds and methods of using them. The sirtuin-modulating compounds can be used to increase cell lifespan and to treat and / or prevent a variety of diseases and conditions, including, for example, diseases or conditions associated with aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular Diseases, blood clotting disorders, inflammation, cancer and / or flushing and diseases or conditions that would benefit from increased mitochondrial activity. The invention also provides compositions comprising a sirtuin-modulating compound and another therapeutic agent. The compound is a compound of general formula (III), wherein R1, R2, R", X, Y, W, Z1 and Z2 are as defined in the specification.
Owner:SIRTRIS PHARMA INC
Quinazolinone, quinolone and related analogs as sirtuin modulators
InactiveCN102227420BOrganic active ingredientsSenses disorderCancer researchBlood clotting disorders
Owner:SIRTRIS PHARMA INC
Chromone analogs as sirtuin modulators
The present invention relates to novel sirtuin-modulating compounds, corresponding pharmaceutical compositions comprising a sirtuin-modulating compound, alone and / or in combination with another therapeutic agent, and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Owner:SIRTRIS PHARMA INC
Compositions and methods for the treatment of blood clotting disorders
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing blood clotting disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of strokes in those with atrial fibrillation due to causes other than heart valve disease, and at least one additional risk factor for stroke (congestive heart failure, hypertension, age, diabetes, and prior stroke), and to prevent the formation of blood clots in the veins in adults operated to replace a hip or knee.
Owner:CELLIXBIO PTE LTD
Pharmaceutical Composition For Treatment Of Blood Clotting Disorder
InactiveUS20090232769A1Reduce the burden onReduce riskBiocidePeptide/protein ingredientsBlood clotting disordersRibavirin
Disclosed is a pharmaceutical composition for the prevention or treatment of blood clotting disorder which can reduce a burden on a patient. The pharmaceutical composition comprises an effective amount of ribavirin or a derivative thereof or a pharmaceutically acceptable salt of ribavirin or the derivative.
Owner:NAGOYA UNIVERSITY
Compositions and methods for the treatment of blood clotting disorders
Owner:CELLIXBIO PTE LTD
Substituted bridged urea analogs useful as sirtuin modulators
InactiveCN105392788BOrganic active ingredientsOrganic chemistryDiabetes mellitusCardio vascular disease
The present invention provides novel substituted bridged ureas and related analogs and methods of their use. The sirtuin-modulating compounds are useful for increasing cell lifespan, and for treating and / or preventing a variety of diseases and disorders, including, for example, diseases or disorders associated with aging or stress, diabetes, obesity, neurodegenerative diseases, Cardiovascular disease, blood clotting disorders, inflammation, cancer and / or flushing, and diseases or disorders that benefit from increased mitochondrial activity. Compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent are also provided.
Owner:GLAXO SMITHKLINE LLC
Quinazolinone, quinolone and related analogs as sirtuin modulators
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Owner:SIRTRIS PHARMA INC
Thiazolopyridine sirtuin modulating compounds
Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and / or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
Owner:SIRTRIS PHARMA INC
Thiazolopyridine sirtuin modulating compounds
Owner:SIRTRIS PHARMA INC
Substituted bridged urea analogs as sirtuin modulators
The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and / or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and / or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. (I)
Owner:GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD
Methods and Compositions for Improving Pial Collateral Circulation and Treating Blood Clotting Disorders
InactiveUS20150139938A1Improving cerebrovascular collateral circulationReduce riskHeavy metal active ingredientsBiocideTissue inhibitor of metalloproteinasePharmacology
The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.
Owner:OHIO STATE INNOVATION FOUND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com